Factors associated with advanced liver fibrosis in patients with non-alcoholic liver disease

Raszeja‐Wyszomirska, Joanna; Stachowska, Ewa; Safranow, Krzysztof; Milkiewicz, Piotr

doi:10.5114/pg.2011.24306

Cited by 4 publications

(4 citation statements)

References 41 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(2011) also reported that serum HA was an independent risk factor for more advanced fibrosis in their study patients. 35 Among Egyptian studies, our results agreed with those of Esmatet al (2007) who reported that serum HA could be used as a single biomarker, fulfilling the criteria for a good predictor of fibrosis andthat young patients with low levels of serum HA were at a very low risk of fibrosis. 36 We also found statistically significant higher values of serum HA in patients with Nonalcoholic Steatohepatitis (NASH) compared with patients with Nonalcoholic Fatty Liver Disease (NAFLD).…”

supporting

confidence: 91%

Correlation between Serum Hyaluronic Acid with Steatosis, Non alcoholic Steato-hepatitis and Fibrosis in Patients with Chronic Hepatitis C Virus Infection

Mahmoud¹

2016

View full text Add to dashboard Cite

Background: Hyaluronic acid (HA) is an attractive potential marker for noninvasive diagnosis of liver fibrosis instead of liver biopsy for both patients and physicians. Aim: To assess the role of HA for diagnosing the progression of steatosis to steato-hepatitis (SH) and fibrosis in patients with Chronic Hepatitis C virus (HCV) infection. Methods: 90 patients with chronic HCV infection, 77 (85.6%) males and 13 (14.4%) females, were included. Blood samples were collected for routine laboratory investigations, liver function tests and serum HA measurements. A liver biopsy was taken for histopathological examination. Results: Steatosis was found in 37 patients (41.1%), fibrosis in 29 patients (32.2%) and SH in 51 patients (56.7%). The mean serum HA for all patients was 86.4±48.2 ng/L. HA levels were significantly higher in patients with fibrosis (95.6±53 vs 54.5±3.5) and SH (88.7±52 vs 49.9±12) than those without (P value = 0.001and 0.001 respectively). HA levels were also significantly higher in patients with an advanced degree of fibrosis, SH and steatosis as compared to those with mild degrees (P value = 0.000, 0.001 and 0.01 respectively). Positive correlations were found between serum HA and the degree of fibrosis, SH and steatosis (P value =0.000 and r = + 0.758, 0.701and 0.727 respectively). The mean HA cut off value for the diagnosis of fibrosis and SH was taken to be 70 and 60 ng/L providing a diagnostic accuracy of 94.1% and 91.6% respectively. Conclusions: Serum HA level is a good noninvasive marker for the diagnosis of fibrosis and steato-hepatitis in patients with chronic HCV infection.

show abstract

supporting

confidence: 91%

Correlation between Serum Hyaluronic Acid with Steatosis, Non alcoholic Steato-hepatitis and Fibrosis in Patients with Chronic Hepatitis C Virus Infection

Mahmoud¹

2016

View full text Add to dashboard Cite

show abstract

“…However, up to now, these methods are not the effective way for treating NAFLD. The drugs in the current market have always adverse effects or contraindications, and there is still no consensus on the most effective drug therapy [33] . Therefore, it is necessary to develop new drugs for NAFLD treatment with little or no side effects.…”

Section: Discussionmentioning

confidence: 99%

Mechanism of action of gypenosides on type 2 diabetes and non-alcoholic fatty liver disease in rats

et al. 2015

WJG

View full text Add to dashboard Cite

AIM:To explore the mechanism of action of gypenosides (GPs) on type 2 diabetes mellitus and non-alcoholic fatty liver disease (T2DM-NAFLD) in rats. METHODS:Sixty rats were randomly divided into a healthy group, an untreated disease model group and GP-treatment groups. The study involved the evaluation of biochemical parameters, including serum aspartate transaminase (AST), alanine transferase (ALT), blood glucose (BG), triglycerides (TG) and total cholesterol (TC). Additionally, the protective effect of the treatments were confirmed histopathologically and the expression of TNF-α and NF-κB in the rat liver was analyzed using immunohistochemistry. The expression of proliferatoractivated receptor gamma (PPARγ) and cytochrome P450 (CYP450) 1A1 mRNA was determined by quantitative RT-PCR. RESULTS:GP treatments at oral doses of 200, 400, and 800 mg/kg per day significantly decreased the levels of serum AST and ALT (P < 0.05, P < 0.01), especially at the dose of 800 mg/kg per day. To a similar extent, GP at 800 mg/kg per day reduced the levels of BG (4.19 ± 0.47, P < 0.01), TG (80.08 ± 10.05, P < 0.01), TC (134.38 ± 16.39, P < 0.01) and serum insulin (42.01 ± 5.04, P < 0.01). The expression of TNF-α and NF-κB measured by immunohistochemistry was significantly reduced by GPs in a dose-dependent manner, and the expression of PPARγ and CYP4501A1 mRNA, as measured using quantitative real-time PCR, were significantly down-regulated by GPs. Moreover, GPs decreased the infiltration of liver fats and reversed the histopathological changes in a dosedependent manner. CONCLUSION:This study suggests that GPs have a protective effect against T2DM-NAFLD by down-regulating the expression of TNF-α and NF-κB proteins, and PPARγ and CYP4501A1 mRNAs. Core tip: Gypenosides (GPs) are one of the most pharmacologically active components in G. pentaphyllum . Basic Study ORIGINAL ARTICLEHe Q et al . Mechanism of action of GPs on T2DM-NAFLD Intervention with GPs significantly decreased the levels of aspartate aminotransferase, alanine aminotransferase, blood glucose, insulin, triglycerides and total cholesterol in type 2 diabetes mellitus and non-alcoholic fatty liver disease (T2DM-NAFLD) model rats, down-regulated the expression of TNF-α, NF-κB, rabbit anti-proliferator activated receptory (PPARγ) and rabbit anti-cytochrome P4501A1 (CYP1A1) mRNA, decreased the infiltration of liver fats and reversed the histopathological changes in a dose-dependent manner. These findings suggest that GPs have a protective effect against T2DM-NAFLD by downregulating the expression of TNF-α and NF-κB proteins, and PPARγ and CYP4501A1 mRNAs.He Q, Li JK, Li F, Li RG, Zhan GQ, Li G, Du WX, Tan HB. Mechanism of action of gypenosides on type 2 diabetes and non-alcoholic fatty liver disease in rats.

show abstract

“…Interestingly, NAFLD being a hepatic component of the MetS, is also an independent risk factor for CVD [118,121]. Pathogenic concepts of NAFLD include overnutrition and underactivity, insulin resistance and genetic factors [122], while the common thread that connects the disorders that define MetS is the presence of insulin resistance [119]. Most NAFLD patients are hyperinsulinaemic and more insulin resistant compared with non-steatotic healthy patients, and there is a near-universal association between NAFLD and insulin resistance, irrespective of obesity [118,123].…”

Section: V2 Oxidative Alterations Visceral Obesity and Non-alcoholmentioning

confidence: 98%

Evaluation of the Possible Contribution of Antioxidants Administration in Metabolic Syndrome

Haidara¹,

Mikhailidis²,

Yassin³

et al. 2011

CPD

View full text Add to dashboard Cite

The metabolic syndrome (MetS) is common, and its associated risk burdens of diabetes and cardiovascular disease (CVD) are a major public health problem. The hypothesis that main constituent parameters of the MetS share common pathophysiologic mechanisms provides a conceptual framework for the future research. Exercise and weight loss can prevent insulin resistance and reduce the risk of diseases associated with the MetS. Interrupting intracellular and extracellular reactive oxygen species (ROS) overproduction could also contribute to normalizing the activation of metabolic pathways leading to the onset of diabetes, endothelial dysfunction, and cardiovascular (CV) complications. On the other hand, it is difficult to counteract the development of CV complications by using conventional antioxidants. Indeed, interest has focused on strategies that enhance the removal of ROS using either antioxidants or drugs that enhance endogenous antioxidant defense. Although these strategies have been effective in laboratory experiments, several clinical trials have shown that they do not reduce CV events, and in some cases antioxidants have actually worsened the outcome. More research is needed in this field.

show abstract

Factors associated with advanced liver fibrosis in patients with non-alcoholic liver disease

Cited by 4 publications

References 41 publications

Correlation between Serum Hyaluronic Acid with Steatosis, Non alcoholic Steato-hepatitis and Fibrosis in Patients with Chronic Hepatitis C Virus Infection

Correlation between Serum Hyaluronic Acid with Steatosis, Non alcoholic Steato-hepatitis and Fibrosis in Patients with Chronic Hepatitis C Virus Infection

Mechanism of action of gypenosides on type 2 diabetes and non-alcoholic fatty liver disease in rats

Evaluation of the Possible Contribution of Antioxidants Administration in Metabolic Syndrome

Contact Info

Product

Resources

About